Literature DB >> 31690821

CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives.

Mohamad Mohty1, Jordan Gautier2, Florent Malard3, Mahmoud Aljurf4, Ali Bazarbachi5, Christian Chabannon6, Mohamed A Kharfan-Dabaja7, Bipin N Savani8, He Huang9, Saad Kenderian10, Arnon Nagler11, Miguel-Angel Perales12,13.   

Abstract

The approval of tisagenlecleucel and axicabtagene ciloleucel represents a breakthrough in the field of immune and cellular therapy for hematologic malignancies. These anti-CD19 chimeric antigen receptor-T cells (CAR) proved to be highly effective in the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and specific histologic subtypes of B-cell non-Hodgkin lymphomas. This expert review aims to summarize the current available research evidence in this field, with a special focus on the different challenges faced by treating physicians, and we also provide future perspectives.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31690821     DOI： 10.1038/s41375-019-0615-5

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


  46 in total

Review 1.  Mechanisms of resistance to CAR T cell therapy.

Authors:  Nirali N Shah; Terry J Fry
Journal:  Nat Rev Clin Oncol       Date:  2019-06       Impact factor: 66.675

Review 2.  Gene-engineered T cells for cancer therapy.

Authors:  Michael H Kershaw; Jennifer A Westwood; Phillip K Darcy
Journal:  Nat Rev Cancer       Date:  2013-08       Impact factor: 60.716

Review 3.  CAR T cell immunotherapy for human cancer.

Authors:  Carl H June; Roddy S O'Connor; Omkar U Kawalekar; Saba Ghassemi; Michael C Milone
Journal:  Science       Date:  2018-03-23       Impact factor: 47.728

Review 4.  CAR therapy: the CD19 paradigm.

Authors:  Michel Sadelain
Journal:  J Clin Invest       Date:  2015-09-01       Impact factor: 14.808

Review 5.  CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy.

Authors:  R H Scheuermann; E Racila
Journal:  Leuk Lymphoma       Date:  1995-08

6.  Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial.

Authors:  E Tavernier; J-M Boiron; F Huguet; K Bradstock; N Vey; T Kovacsovics; A Delannoy; N Fegueux; P Fenaux; A Stamatoullas; O Tournilhac; A Buzyn; O Reman; C Charrin; C Boucheix; J Gabert; V Lhéritier; J-P Vernant; H Dombret; X Thomas
Journal:  Leukemia       Date:  2007-07-05       Impact factor: 11.528

7.  Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study.

Authors:  Adele K Fielding; Susan M Richards; Rajesh Chopra; Hillard M Lazarus; Mark R Litzow; Georgina Buck; I Jill Durrant; Selina M Luger; David I Marks; Ian M Franklin; Andrew K McMillan; Martin S Tallman; Jacob M Rowe; Anthony H Goldstone
Journal:  Blood       Date:  2006-10-10       Impact factor: 22.113

8.  Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells.

Authors:  Jae H Park; Renier J Brentjens
Journal:  Discov Med       Date:  2010-04       Impact factor: 3.222

9.  Fully human CD19-specific chimeric antigen receptors for T-cell therapy.

Authors:  D Sommermeyer; T Hill; S M Shamah; A I Salter; Y Chen; K M Mohler; S R Riddell
Journal:  Leukemia       Date:  2017-02-16       Impact factor: 11.528

10.  Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions.

Authors:  Maria Castella; Anna Boronat; Raquel Martín-Ibáñez; Vanina Rodríguez; Guillermo Suñé; Miguel Caballero; Berta Marzal; Lorena Pérez-Amill; Beatriz Martín-Antonio; Julio Castaño; Clara Bueno; Olga Balagué; Europa Azucena González-Navarro; Carles Serra-Pages; Pablo Engel; Ramon Vilella; Daniel Benitez-Ribas; Valentín Ortiz-Maldonado; Joan Cid; Jaime Tabera; Josep M Canals; Miquel Lozano; Tycho Baumann; Anna Vilarrodona; Esteve Trias; Elías Campo; Pablo Menendez; Álvaro Urbano-Ispizua; Jordi Yagüe; Patricia Pérez-Galán; Susana Rives; Julio Delgado; Manel Juan
Journal:  Mol Ther Methods Clin Dev       Date:  2018-12-06       Impact factor: 6.698
View more
  24 in total

1.  Allogeneic haematopoietic stem cell transplantation improves outcome of adults with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia entering remission following CD19 chimeric antigen receptor T cells.

Authors:  Bin Gu; Bing-Yu Shi; Xiang Zhang; Shi-Yuan Zhou; Jian-Hong Chu; Xiao-Jin Wu; Cheng-Cheng Fu; Hui-Ying Qiu; Yue Han; Su-Ning Chen; Lei Yu; Xiao Ma; De-Pei Wu
Journal:  Bone Marrow Transplant       Date:  2020-06-24       Impact factor: 5.483

Review 2.  Emerging molecular subtypes and therapeutic targets in B-cell precursor acute lymphoblastic leukemia.

Authors:  Jianfeng Li; Yuting Dai; Liang Wu; Ming Zhang; Wen Ouyang; Jinyan Huang; Saijuan Chen
Journal:  Front Med       Date:  2021-01-05       Impact factor: 4.592

3.  A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells.

Authors:  David J DiLillo; Kara Olson; Katja Mohrs; Thomas Craig Meagher; Kevin Bray; Olga Sineshchekova; Thomas Startz; Jessica Kuhnert; Marc W Retter; Stephen Godin; Prachi Sharma; Frank Delfino; John Lin; Eric Smith; Gavin Thurston; Jessica R Kirshner
Journal:  Blood Adv       Date:  2021-03-09

Review 4.  Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.

Authors:  Miguel-Angel Perales; Larry D Anderson; Tania Jain; Saad S Kenderian; Olalekan O Oluwole; Gunjan L Shah; Jakub Svoboda; Mehdi Hamadani
Journal:  Transplant Cell Ther       Date:  2022-06-26

Review 5.  Advances in Immunotherapy for Diffuse Large B Cell Lymphoma.

Authors:  Geoffrey Shouse; Alex F Herrera
Journal:  BioDrugs       Date:  2021-07-15       Impact factor: 5.807

6.  Severe Motor Weakness Due to Disturbance in Peripheral Nerves Following Tisagenlecleucel Treatment.

Authors:  Mai Kuboki; Yoshihiro Umezawa; Yotaro Motomura; Keigo Okada; Ayako Nogami; Toshikage Nagao; Osamu Miura; Masahide Yamamoto
Journal:  In Vivo       Date:  2021 Nov-Dec       Impact factor: 2.155

7.  Composite CD79A/CD40 co-stimulatory endodomain enhances CD19CAR-T cell proliferation and survival.

Authors:  Jakrawadee Julamanee; Seitaro Terakura; Koji Umemura; Yoshitaka Adachi; Kotaro Miyao; Shingo Okuno; Erina Takagi; Toshiyasu Sakai; Daisuke Koyama; Tatsunori Goto; Ryo Hanajiri; Michael Hudecek; Peter Steinberger; Judith Leitner; Tetsuya Nishida; Makoto Murata; Hitoshi Kiyoi
Journal:  Mol Ther       Date:  2021-05-01       Impact factor: 12.910

8.  Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery.

Authors:  Victoria Gutgarts; Tania Jain; Junting Zheng; Molly A Maloy; Josel D Ruiz; Martina Pennisi; Edgar A Jaimes; Miguel-Angel Perales; Jaffer Sathick
Journal:  Biol Blood Marrow Transplant       Date:  2020-02-20       Impact factor: 5.742

9.  Vγ9Vδ2 T Cells Concurrently Kill Cancer Cells and Cross-Present Tumor Antigens.

Authors:  Gitte Holmen Olofsson; Manja Idorn; Ana Micaela Carnaz Simões; Pia Aehnlich; Signe Koggersbøl Skadborg; Elfriede Noessner; Reno Debets; Bernhard Moser; Özcan Met; Per Thor Straten
Journal:  Front Immunol       Date:  2021-06-02       Impact factor: 7.561

Review 10.  Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.

Authors:  Ya Zhang; Xin Wang; Zixun Yin
Journal:  Biomark Res       Date:  2021-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.